# Cancer Pharmacology

> **NIH NIH T32** · WEILL MEDICAL COLL OF CORNELL UNIV · 2020 · $531,895

## Abstract

Faculty from two institutions, Weill Cornell Medicine ((WCM), formerly, Weill Cornell Medical College
(WCMC)), and Memorial Sloan-Kettering Cancer Center (MSKCC), who share a single PhD program, are
requesting funds to support an innovative and collaborative training program in cancer pharmacology.
Our cancer pharmacology training grant/program (CPTG) includes an integrated set of training activities
for PhD students and postdoctoral fellows. The strength and research diversity of the 24 faculty research
advisors provide opportunities for research in a variety of areas, including the development of new cancer
therapeutic agents (e.g. organic synthesis, monoclonal antibody technology, differentiation therapy,
immunotherapies, & the screening of chemical libraries), the analysis of molecular mechanisms to identify
new drug targets, exploration of how drugs act on cancer cells, cancer prevention, and clinical trials.
This CPTG is unusual in that it features broad training ranging from molecular pharmacology to animal
models of cancer and human clinical trials. Many faculty on the CPTG are physician-scientists who treat
patients as well as perform research. The PhD program includes course work, three lab rotations, an
admission to candidacy exam, thesis research, and a robust mentoring program. A major PhD course,
Cancer Pharmacology (part of this program) represents a strong commitment of the 24 CPTG faculty to the
training of students and fellows. Students and fellows present their research at the annual two-day
Pharmacology Program retreat and at scientific meetings. Pre- and postdoctoral CPTG fellows attend
weekly journal clubs and take courses related to cancer pharmacology. We are continuing to expand the
successful Bench-to-Bedside, a course in drug development/entrepreneurship. Since the last competitive
renewal, we established From Molecule to Prescription, a course taught by pharmacologists working in drug
companies. We also started a course on biostatistics, bioinformatics, and quantitative biology. We actively
use External and Internal Advisory Committees, plus a CARR (Committee for Admissions, Recruitment,
& Retention). This CPTG has a number of strengths, most notably extremely large pools of well-qualified
training grant-eligible applicants for both the predoctoral and postdoctoral positions; an expanding group
of highly collaborative and talented CPTG faculty research advisors; a high productivity in terms of
publications by trainees; and the tremendously vibrant and collaborative intellectual atmosphere in the
tri-institutional research area. Thus, this CPTG will continue to provide PhD students and postdoctoral
fellows with an in depth understanding of the interrelationships among research on the basic mechanisms
of drug action, drug development, and clinical issues, producing the next generation of clinicians,
clinician-scientists, and pharmacologists in basic research who will be well prepared to carry out
independent research and...

## Key facts

- **NIH application ID:** 9936668
- **Project number:** 2T32CA062948-26
- **Recipient organization:** WEILL MEDICAL COLL OF CORNELL UNIV
- **Principal Investigator:** LORRAINE J GUDAS
- **Activity code:** T32 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $531,895
- **Award type:** 2
- **Project period:** 1994-09-01 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9936668

## Citation

> US National Institutes of Health, RePORTER application 9936668, Cancer Pharmacology (2T32CA062948-26). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/9936668. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*